CD163 and chronic myelogenous leukemia, BCR-ABL1 positive: The number of CD163+ macrophages was remarkably increased in BMB samples from CML-CP (19.91 ± 3.33)% to CML-AP (37.26 ± 4.70)% to CML-BP (59.97 ± 6.79)% (Figures 2(a), 2(b), 2(c), and 2(d)), respectively.